Advertisement

International Journal of Hematology

, Volume 108, Issue 4, pp 416–422 | Cite as

Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method

  • Hidekazu Itamura
  • Masaru Ide
  • Akemi Sato
  • Naoko Sueoka-Aragane
  • Eisaburo Sueoka
  • Aya Nishida
  • Taro Masunari
  • Sadao Aoki
  • Jun Takizawa
  • Junji Suzumiya
  • Shinya Kimura
Original Article
  • 108 Downloads

Abstract

Hairy cell leukemia (HCL) is a rare B-cell lymphoid malignancy that is difficult to distinguish from other morphological variants. The frequency of HCL has not been determined accurately in Japan. Recent studies revealed that the BRAF V600E mutation is the causal genetic event in HCL. We assessed the BRAF mutation in Japanese patients with HCL and related diseases using the quenching probe (QP) method, a single-nucleotide polymorphism detection system, and evaluated the incidence rate of HCL among Japanese patients with chronic lymphocytic leukemia, and related diseases. We identified 18 cases (33.3%) harboring the BRAF mutation among 54 patients diagnosed with, or suspected of having HCL. Of BRAF V600E-positive patients, 7 were only detected using the QP method, not by direct sequencing, whereas 11 were positive using both tests. In a larger cohort of Japanese patients diagnosed with chronic lymphoid leukemia or related diseases, the frequency of HCL was 4%. Patients with the BRAF V600E mutation had a significantly higher frequency of neutropenia, thrombocytopenia, and elevated soluble interleukin-2 receptor and common B-cell surface markers than patients without the mutation. Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.

Keywords

BRAF V600E Hairy cell leukemia Low-grade B-cell malignancy Quenching probe Japan 

Notes

Acknowledgements

The authors thank all of the patients and all of the investigators at participating institutions.

Compliance with ethical standards

Conflict of interest

The authors declare no potential conflicts of interest.

Supplementary material

12185_2018_2506_MOESM1_ESM.docx (355 kb)
Supplementary material 1 (DOCX 354 KB)
12185_2018_2506_MOESM2_ESM.docx (14 kb)
Supplementary material 2 (DOCX 14 KB)

References

  1. 1.
    Schrek R, Donnelly WJ. “Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodes. Blood. 1966;27:199–211.PubMedGoogle Scholar
  2. 2.
    Forconi F. Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol Oncol. 2011;29:55–66.CrossRefPubMedGoogle Scholar
  3. 3.
    Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol. 2012;156:186–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: World Heal. Organ. Classification Tumours Haematop. Lymphoid Tissue; 2008.Google Scholar
  5. 5.
    Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res. 1990;50:3605–9.PubMedGoogle Scholar
  6. 6.
    Paltiel O, Adler B, Barchana M, Dann EJ. A population-based study of hairy cell leukemia in Israel. Eur J Haematol. 2006;77:372–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Cawley JC, Burns GF, Hayhoe FGJ. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980;4:547–59.CrossRefPubMedGoogle Scholar
  8. 8.
    Machii T, Tokumine Y, Inoue R, Kitani T. A unique variant of hairy cell leukemia in Japan. Jpn J Med. 1990;29:379–83.CrossRefPubMedGoogle Scholar
  9. 9.
    Machii T, Tokumine Y, Inoue R, Kitani T. Predominance of a distinct subtype of hairy cell leukemia in Japan. Leukemia. 1993;7:181–6.PubMedGoogle Scholar
  10. 10.
    Machii T, Yamaguchi M, Inoue R, Tokumine Y, Kuratsune H, Nagai H, et al. Polyclonal B-cell lymphocytosis with features resembling hairy cell leukemia-Japanese variant. Blood. 1997;89:2008.PubMedGoogle Scholar
  11. 11.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–15.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med. 2014;6:238ra71–1.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119:188–91.CrossRefPubMedGoogle Scholar
  15. 15.
    Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119:192–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Ide M, Koba S, Sueoka-Aragane N, Sato A, Nagano Y, Inoue T, et al. Mutation profile of B-Raf gene analyzed by fully automated system and clinical features in japanese melanoma patients. Pathol Oncol Res. 2017;23:181–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Tanaka R, Kuroda J, Stevenson W, Ashihara E, Ishikawa T, Taki T, et al. Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res. 2008;32:1462–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Okada K, Kunitomi A, Sakai K, Muranushi H, Okamoto Y, Tsukamoto T, et al. Hairy cell leukemia with systemic lymphadenopathy: detection of BRAF mutations in both lymph node and peripheral blood specimens. Intern Med. 2015;54:1397–402.CrossRefPubMedGoogle Scholar
  19. 19.
    Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373:1733–47.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Samuel J, Macip S, Dyer MJS. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 2014;370:286–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Suzuki SI, Matsusaka S, Hirai M, Shibata H, Takagi K, Mizunuma N, et al. A novel approach to detect KRAS/BRAF mutation for colon cancer: highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. Int J Oncol. 2015;47:97–105.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Hashimoto Y, Tsukamoto N, Nakahashi H, Yokohama A, Saitoh T, Handa H, et al. Hairy cell leukemia-related disorders consistently show low CD27 expression. Pathol Oncol Res. 2009;15:615–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Ruiz-Argüelles GJ, Cantú-Rodríguez OG, Gómez-Almaguer D, Certes-Franco J, Góngora-Biachi RA, Pizzuto J, et al. Hairy cell leukemia is infrequent in Mexico and has a geographic distribution. Am J Hematol. 1996;52:316–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Au WY, Kwong YL, Ma SK, Mak YK, Wong KF, Lei KI, et al. Hairy cell leukemia in Hong Kong Chinese: a 12-year retrospective survey. Hematol Oncol. 2000;18:155–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Kao H-W, Dunn P, Kuo M-C, Shih L-Y, Lin T-L, Wu J-H, et al. Classical hairy cell leukemia and its variant: a 17-year retrospective survey in Taiwan Chinese. Acta Haematol. 2011;126:186–93.CrossRefPubMedGoogle Scholar
  27. 27.
    Tamura K, Sawada H, Izumi Y, Fukuda T, Utsunomiya A, Ikeda S, et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol. 2001;67:152–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–45.CrossRefPubMedGoogle Scholar
  29. 29.
    Robbins BA, Ellison DJ, Spinosa JC, Carey CA, Lukes RJ, Poppema S, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 1993;82:1277–87.PubMedGoogle Scholar
  30. 30.
    Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114:4687–95.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46:8–10 (Nature Publishing Group).CrossRefPubMedGoogle Scholar
  32. 32.
    Shtivelman E, Davies MQa, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways and therapeutic targets in melanoma. Oncotarget. 2014;5:1701–52.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, et al. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer. 2015;15:258–66.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Badalian-Very G, Vergilio J. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:6–8.CrossRefGoogle Scholar
  35. 35.
    Haroche J, Charlotte F, Arnaud L, Von Deimling A, Hélias-rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses brief report high prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700–3.CrossRefPubMedGoogle Scholar
  36. 36.
    Szturz P, Hlavatý L, Prášek J, Dvořáková D. Erdheim–Chester disease and Schnitzler syndrome: so near, and yet so far. Int J Hematol. 2013;98:379–81.CrossRefPubMedGoogle Scholar
  37. 37.
    Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim–Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495–500.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Hidekazu Itamura
    • 1
  • Masaru Ide
    • 2
  • Akemi Sato
    • 3
  • Naoko Sueoka-Aragane
    • 1
  • Eisaburo Sueoka
    • 3
  • Aya Nishida
    • 4
  • Taro Masunari
    • 5
  • Sadao Aoki
    • 6
  • Jun Takizawa
    • 7
  • Junji Suzumiya
    • 8
  • Shinya Kimura
    • 1
  1. 1.Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of MedicineSaga UniversitySagaJapan
  2. 2.Department of Internal MedicineOda HospitalKashimaJapan
  3. 3.Department of Clinical Laboratory Medicine, Faculty of MedicineSaga UniversitySagaJapan
  4. 4.Department of HematologyToranomon HospitalTokyoJapan
  5. 5.Department of HematologyChugoku Central HospitalHiroshimaJapan
  6. 6.Department of Pathophysiology, Faculty of Pharmaceutical SciencesNiigata University of Pharmacy and Applied Life SciencesNiigataJapan
  7. 7.Department of Hematology, Endocrinology and Metabolism, Faculty of MedicineNiigata UniversityNiigataJapan
  8. 8.Department of Oncology/Hematology, School of MedicineShimane UniversityIzumoJapan

Personalised recommendations